Field Service Medical 2014

Feb 9th, 2014Feb 11th, 2014
San Diego, CA
US
http://www.wbresearch.com/fieldservicemedical/downloadagenda.aspx
Phone:646-200-7530
Field Service Medical is North America’s only event for medical device service and support executives. It is tailored to address the challenges of manufacturers looking to increase service revenue and improve their overall service and support capabilities.
Latest in Home
Snmmi Thumb
SNMMI: Biomarkers predict I-131 response in obese thyroid cancer patients
June 2, 2026
The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails
Podcast: Telltale signs your MRI safety standards are inadequate
June 2, 2026
RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.
SNMMI: Theranostic approach may treat PSMA-negative prostate cancer
June 2, 2026
Asco Thumb
ASCO: Use of GLP-1 drugs linked to lower breast cancer cases
June 2, 2026
More in Home
SNMMI: Biomarkers predict I-131 response in obese thyroid cancer patients
By Kate Madden Yee
Metabolic status should be considered in post-therapy evaluation of obese differentiated thyroid cancer patients, researchers noted.
June 2, 2026
Snmmi Thumb
Podcast: Telltale signs your MRI safety standards are inadequate
By Liz Carey
Check your MRI safety sense.
June 2, 2026
The Invisible Force Podcast Album Cover Auntminnie Jan 2026 Thumbnails
SNMMI: Theranostic approach may treat PSMA-negative prostate cancer
By Amerigo Allegretto
A theranostic approach could help improve PET imaging for neuroendocrine prostate cancer care.
June 2, 2026
RET-targeted PET tracer highlights neuroendocrine prostate cancer tumors. Representative PET imaging shows strong tumor uptake of the RET-binding peptide tracer [⁶⁸Ga]Ga-DOTA-RET-L7 in a neuroendocrine prostate cancer (NEPC) model, supporting highly specific, high-contrast detection.
ASCO: Use of GLP-1 drugs linked to lower breast cancer cases
By Erik L. Ridley
A large retrospective study found sharply lower incidence of breast cancer among women who had received GLP-1 drugs.
June 2, 2026
Asco Thumb
SNMMI: CAIX-targeted PET tracer detects clear cell renal cell carcinoma
By Liz Carey
Researchers aim for "more precise molecular map" for kidney cancer.
June 1, 2026
A 68Ga-RCC78 PET scan (C) of a patient four years post-radical right nephrectomy. During follow-up, new nodules were detected in the left adrenal gland and kidney. CAIX-targeted scan clearly visualized metastatic lesions in the mediastinum, pancreas, adrenal gland, and kidney (SUVmax > 30), demonstrating the tracer's ability to maintain high tumor uptake despite significantly reduced abdominal background.
SNMMI: Low-cost absorbents clear over 90% of Lu-177 from wastewater
By Kate Madden Yee
An increase in the use of radionuclide therapy has added burden to wastewater management systems.
June 1, 2026
Snmmi Thumb
SNMMI: PET tracer that detects deep vein thrombosis wins Image of the Year
By Will Morton
F-18 GP1 is derived from elarofiban and selectively binds to glycoprotein IIb/IIIa receptors on activated platelets.
June 1, 2026
(Left) F-18 GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of the left leg (from the thigh to the calf), as well as several clots in the right calf. Venous ultrasound confirms blood clots in left thigh, knee and calf veins. PET/CT also detects clots in both lungs, which are confirmed by contrast-enhanced CT image. (Right) 18F-GP1 PET/CT images from a 70-year-old woman show widespread blood clots throughout the body. In addition to clots in the deep veins of both legs and the arteries of both lungs (A), the scan also detected unexpected clots in several other areas, including blood vessels near the skull/head (B), spine (C), heart (D), and pelvis (E). Further evaluation revealed that the patient had antiphospholipid syndrome, an autoimmune condition that increases the risk of abnormal blood clot formation.
SNMMI: Novel radiotracer effectively images overactive adrenal glands
By Liz Carey
University of Michigan researchers report on first-in-human study of SOAT1-targeted nevanimibe C-11.
June 1, 2026
Static PET-CT image of patient with hypercortisolism taken at 60 minutes post-injection.
SNMMI: Mouaz Al-Mallah discusses cardiac PET
By Will Morton
In this interview, Mouaz Al-Mallah, MD, discusses cardiac PET imaging, including new efforts to create more access for patients and the impact of new radiotracers.
June 1, 2026
Mouaz Al Mallah Thumb1
ASCO: Proton therapy, IMRT both work well for prostate cancer
By Erik L. Ridley
Both modalities yielded similar outcomes, according to preliminary results from a large, prospective trial.
June 1, 2026
Asco Thumb
SNMMI: Point-of-care PET system may guide interventional procedures
By Amerigo Allegretto
A portable, point-of-care PET system showed success in imaging organs and may be helpful in interventional guidance.
June 1, 2026
(a) Benchtop portable POC-PET prototype system. (b) Phantom imaging experiment setup. (c) Comparison of conventional full-data MLEM reconstruction with incremental OSEM reconstruction.
SNMMI: Brain-dedicated PET scanner cuts claustrophobia, boosts comfort
By Kate Madden Yee
The findings "support the use of brain-dedicated PET scanners as a patient-centered alternative," researchers wrote.
June 1, 2026
Snmmi Thumb
Page 1 of 230
Next Page